{"id":"matching-placebo-twice-daily","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebo is a pharmaceutical preparation designed to be identical in appearance, taste, and administration schedule to the active investigational drug, but contains no active pharmaceutical ingredient. It serves as a control arm in randomized controlled trials to account for placebo effect and natural disease progression. The twice-daily dosing schedule matches the active comparator to maintain blinding.","oneSentence":"Matching placebo has no active pharmacological mechanism; it is an inert control formulation used in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:18.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04669158","phase":"PHASE1, PHASE2","title":"Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-07-30","conditions":"Non Alcoholic Steatohepatitis, Fibrosis","enrollment":53},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07332091","phase":"PHASE2","title":"Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2026-01-22","conditions":"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis","enrollment":84},{"nctId":"NCT05965726","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID-19, Long COVID","enrollment":964},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT03747458","phase":"PHASE3","title":"OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2018-12-31","conditions":"Bilateral Nasal Polyposis","enrollment":72},{"nctId":"NCT07123155","phase":"PHASE2","title":"Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)","status":"RECRUITING","sponsor":"Shionogi","startDate":"2025-10-30","conditions":"Pompe Disease","enrollment":45},{"nctId":"NCT07325266","phase":"PHASE2","title":"Human Laboratory Study of Apremilast for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Alcohol Use Disorder, Alcohol Misuse","enrollment":100},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT06850805","phase":"PHASE3","title":"Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2025-07-28","conditions":"Chronic Rhinosinusitis Without Nasal Polyps","enrollment":84},{"nctId":"NCT07393360","phase":"NA","title":"Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2025-12-11","conditions":"Obesity & Overweight","enrollment":144},{"nctId":"NCT07226895","phase":"PHASE1, PHASE2","title":"A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis","status":"RECRUITING","sponsor":"Monument Therapeutics Limited","startDate":"2026-03","conditions":"Clinical High Risk for Psychosis (CHR)","enrollment":150},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT07482644","phase":"NA","title":"Efficacy and Safety of an Essential Oil-Based Product System for Immune Support","status":"NOT_YET_RECRUITING","sponsor":"dōTERRA International","startDate":"2026-05-04","conditions":"Immune System Function, Inflammation","enrollment":40},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT07181382","phase":"PHASE3","title":"Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","status":"SUSPENDED","sponsor":"GB002, Inc.","startDate":"2026-02","conditions":"Pulmonary Hypertension Associated With Interstitial Lung Disease","enrollment":480},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT05934526","phase":"PHASE3","title":"Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)","status":"COMPLETED","sponsor":"GB002, Inc.","startDate":"2023-12-28","conditions":"Pulmonary Arterial Hypertension","enrollment":390},{"nctId":"NCT05983588","phase":"PHASE2","title":"PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Technical University of Munich","startDate":"2023-12-12","conditions":"Corticobasal Syndrome (CBS)","enrollment":32},{"nctId":"NCT07214571","phase":"PHASE2","title":"A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease","status":"RECRUITING","sponsor":"Shionogi","startDate":"2025-12-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":192},{"nctId":"NCT07382167","phase":"PHASE3","title":"A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults","status":"RECRUITING","sponsor":"Ardelyx","startDate":"2026-01-13","conditions":"Chronic Idiopathic Constipation (CIC)","enrollment":692},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT05618353","phase":"PHASE4","title":"The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-21","conditions":"Coronary Artery Disease","enrollment":700},{"nctId":"NCT06582888","phase":"EARLY_PHASE1","title":"Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-11-19","conditions":"Nicotine Addiction, Craving","enrollment":200},{"nctId":"NCT05757869","phase":"PHASE3","title":"A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-11","conditions":"Atrial Fibrillation","enrollment":20284},{"nctId":"NCT06454669","phase":"PHASE2","title":"Dronabinol as an Adjunct for Reducing Pain","status":"RECRUITING","sponsor":"Christopher D. Verrico","startDate":"2024-06-15","conditions":"Low Back Pain, Chronic Pain, Back Injuries","enrollment":75},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT06708299","phase":"PHASE3","title":"CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)","status":"RECRUITING","sponsor":"Cardiol Therapeutics Inc.","startDate":"2025-04-07","conditions":"Recurrent Pericarditis","enrollment":110},{"nctId":"NCT06834997","phase":"PHASE2","title":"Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Endometriosis, Endometriosis Related Pain, Endometriosis, Pain","enrollment":""},{"nctId":"NCT06511063","phase":"PHASE2","title":"Antiviral Clinical Trial for Long Covid-19","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-01","conditions":"Long Covid","enrollment":90},{"nctId":"NCT07468526","phase":"PHASE3","title":"An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06-01","conditions":"Malaria","enrollment":1019},{"nctId":"NCT07467746","phase":"PHASE2","title":"Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":84},{"nctId":"NCT06345404","phase":"PHASE1","title":"Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD","status":"COMPLETED","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2024-04-16","conditions":"Atopic Dermatitis","enrollment":82},{"nctId":"NCT07452744","phase":"NA","title":"Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Bioagile Therapeutics Pvt. Ltd.","startDate":"2024-08-13","conditions":"Non Alcholic Fatty Liver Disease","enrollment":170},{"nctId":"NCT07463339","phase":"PHASE2","title":"Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-05-01","conditions":"Critical Illness, Mechanical Ventilation","enrollment":70},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT05658575","phase":"PHASE2, PHASE3","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","status":"RECRUITING","sponsor":"Olatec Therapeutics LLC","startDate":"2023-01-06","conditions":"Acute Gout Flare, Gout Attack, Gout Flare","enrollment":300},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT06961708","phase":"PHASE1","title":"A Study of Fosmanogepix in Healthy Adult Chinese Subjects","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2025-04-14","conditions":"Healthy","enrollment":54},{"nctId":"NCT05040321","phase":"PHASE1, PHASE2","title":"Sirtuin-NAD Activator in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-12-01","conditions":"Alzheimer's Disease (Incl Subtypes), Dementia","enrollment":22},{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT07457294","phase":"PHASE3","title":"1% Clascoterone Cream for the Treatment Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","startDate":"2026-05-04","conditions":"Acne Vulgaris","enrollment":692},{"nctId":"NCT06638502","phase":"PHASE1, PHASE2","title":"Safety of HRX215 in Patients After Minor and Major Liver Resection","status":"RECRUITING","sponsor":"HepaRegeniX GmbH","startDate":"2025-05-06","conditions":"Colorectal Liver Metastases, Liver Resection","enrollment":25},{"nctId":"NCT07458594","phase":"NA","title":"Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer","status":"COMPLETED","sponsor":"Beijing Sport University","startDate":"2025-10-30","conditions":"Aerial Duel Performance in Soccer Players","enrollment":96},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT07226440","phase":"PHASE1, PHASE2","title":"Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-01","conditions":"Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals","enrollment":40},{"nctId":"NCT04057898","phase":"PHASE2, PHASE3","title":"Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediciNova","startDate":"2020-05-28","conditions":"Amyotrophic Lateral Sclerosis","enrollment":234},{"nctId":"NCT07258394","phase":"PHASE3","title":"Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2026-01-27","conditions":"Type 1 Diabetes","enrollment":90},{"nctId":"NCT07341386","phase":"PHASE4","title":"Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-04-01","conditions":"Autoimmune Rheumatic Diseases, Recurrent Herpes Simplex, Prevention","enrollment":62},{"nctId":"NCT07441395","phase":"PHASE2","title":"Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","status":"RECRUITING","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2026-02","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema","enrollment":200},{"nctId":"NCT05050136","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2021-09-22","conditions":"Primary Biliary Cholangitis, PBC","enrollment":260},{"nctId":"NCT05031780","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-02-11","conditions":"Sickle Cell Disease","enrollment":286},{"nctId":"NCT07444892","phase":"PHASE2","title":"Levodopa for Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-04-18","conditions":"Diabetic Retinopathy","enrollment":230},{"nctId":"NCT04770779","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-11-30","conditions":"Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia","enrollment":258},{"nctId":"NCT06563895","phase":"PHASE3","title":"Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","status":"RECRUITING","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2025-05-12","conditions":"Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis","enrollment":582},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Ovarian Cancer","enrollment":366},{"nctId":"NCT04770753","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-12-20","conditions":"Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia","enrollment":194},{"nctId":"NCT05144256","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-06-08","conditions":"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","enrollment":49},{"nctId":"NCT03598309","phase":"PHASE2","title":"Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-05","conditions":"Lung Diseases, Lung Cancer, Protection Against","enrollment":19},{"nctId":"NCT07036029","phase":"PHASE1","title":"NAL ER IPF Respiratory Function and Safety Study","status":"RECRUITING","sponsor":"Trevi Therapeutics","startDate":"2025-08-21","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":10},{"nctId":"NCT06286397","phase":"PHASE2","title":"Topical Anti-Androgens in Pilonidal Sinus Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-10","conditions":"Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus","enrollment":75},{"nctId":"NCT06273540","phase":"PHASE1","title":"Phase1, STP7 Cocaine Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Stalicla SA","startDate":"2024-04-15","conditions":"Cocaine Use Disorder","enrollment":21},{"nctId":"NCT07224581","phase":"PHASE3","title":"Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder","status":"RECRUITING","sponsor":"GRIN Therapeutics, Inc.","startDate":"2026-01-05","conditions":"GRIN-related Neurodevelopmental Disorder","enrollment":100},{"nctId":"NCT07216001","phase":"PHASE2","title":"Role of Omega-DEK in Childhood Apraxia of Speech","status":"NOT_YET_RECRUITING","sponsor":"Claudia R. Morris","startDate":"2026-05","conditions":"Childhood Apraxia of Speech, Verbal Apraxia, Autism","enrollment":34},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT07157735","phase":"PHASE2","title":"A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-02-02","conditions":"Parkinson Disease","enrollment":36},{"nctId":"NCT07437313","phase":"NA","title":"Marine Lipids Ease Painful TMD","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-08","conditions":"Temporomandibular Disorder (TMD)","enrollment":100},{"nctId":"NCT06047262","phase":"PHASE2","title":"Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia","status":"RECRUITING","sponsor":"Marc Donath","startDate":"2024-07-09","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT07432529","phase":"PHASE3","title":"Design and Rationale of the COLT Study","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale ASL 6, Livorno","startDate":"2026-06-01","conditions":"Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE)","enrollment":940},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"Autism, Autism Spectrum Disorder, Nonverbal Learning Disability","enrollment":25},{"nctId":"NCT07198607","phase":"NA","title":"Pistacia Lentiscus Oil Nasal Drops for Preventing Recurrence of Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2024-03-04","conditions":"Chronic Rhinosinusitis Without Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)","enrollment":100},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT04966585","phase":"PHASE4","title":"Pilot Study of Posaconazole in Crohn's Disease","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-08-17","conditions":"Crohn Disease, CARD9 S12N Risk Allele","enrollment":10},{"nctId":"NCT07430696","phase":"PHASE2","title":"INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY","status":"NOT_YET_RECRUITING","sponsor":"University of Kelaniya","startDate":"2026-05-01","conditions":"Efficacy of Trishul","enrollment":40},{"nctId":"NCT05513560","phase":"PHASE2, PHASE3","title":"RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2023-05-31","conditions":"Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19","enrollment":460},{"nctId":"NCT04562766","phase":"PHASE3","title":"Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-12-14","conditions":"Immune Thrombocytopenia","enrollment":232},{"nctId":"NCT07419633","phase":"NA","title":"This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-05","conditions":"Muscle, Cognitive Functioning, Geriatric","enrollment":120},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":"Coronary Artery Bypass Graft","enrollment":90},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT07418957","phase":"PHASE3","title":"Efficacy and Safety of Vaginal Lactobacillus Dual Probiotic Capsules in Bacterial Vaginosis","status":"COMPLETED","sponsor":"Guangdong Longchuangji Pharmaceutical Co., Ltd.","startDate":"2024-06-12","conditions":"Bacterial Vaginosis (BV)","enrollment":402},{"nctId":"NCT05759468","phase":"PHASE2","title":"NAD Augmentation in Diabetes Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-04-13","conditions":"Type2diabetes, Diabetic Kidney Disease","enrollment":140},{"nctId":"NCT02032823","phase":"PHASE3","title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-04-22","conditions":"Breast Cancer","enrollment":1836},{"nctId":"NCT06685809","phase":"PHASE1","title":"A Phase 1 Study of FZ008-145 in Healthy Subjects.","status":"RECRUITING","sponsor":"Guangzhou Fermion Technology Co., LTD","startDate":"2024-11-25","conditions":"Healthy","enrollment":190},{"nctId":"NCT03527472","phase":"PHASE2","title":"Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2018-08-23","conditions":"Lupus Erythematosus, Systemic","enrollment":111},{"nctId":"NCT03653507","phase":"PHASE3","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-11-28","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":507},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT07023835","phase":"PHASE2","title":"Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2025-09-17","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":240},{"nctId":"NCT05844501","phase":"PHASE4","title":"Ondansetron for the Management of Atrial Fibrillation","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-04-22","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT07357142","phase":"NA","title":"Jing Si Herbal Tea as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2026-03-01","conditions":"Chronic Pelvic Pain Syndrome (CPPS)","enrollment":400},{"nctId":"NCT04663308","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2020-12-18","conditions":"Primary Sclerosing Cholangitis","enrollment":182},{"nctId":"NCT07383974","phase":"NA","title":"The Impact of 12 Week Retention of Nutrients on Skin and the Perception of Physical Health Status","status":"RECRUITING","sponsor":"ChinaNorm","startDate":"2025-11-03","conditions":"Healthy Volunteers, Dietary Supplementation, Skin Health","enrollment":120},{"nctId":"NCT07128199","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2025-12-22","conditions":"NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant","enrollment":360},{"nctId":"NCT06310967","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease","status":"RECRUITING","sponsor":"Intelligem Therapeutics Australia Pty Ltd.","startDate":"2024-11-12","conditions":"Hyperuricemia, Hypouricemia, Renal","enrollment":60},{"nctId":"NCT06553768","phase":"PHASE3","title":"Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2024-10-14","conditions":"Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo (twice daily)","genericName":"Matching Placebo (twice daily)","companyName":"Grünenthal GmbH","companyId":"gr-nenthal-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}